FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2007117923> ?p ?o ?g. }

• W2007117923 endingPage "397" @default.
• W2007117923 startingPage "386" @default.
• W2007117923 abstract "The aims of the current studies were to determine the in vitro and in vivo ocular and non-ocular pharmacological properties of cabergoline using well documented receptor binding, cell-based functional assays, and in vivo models. Cabergoline bound to native and/or human cloned serotonin-2A/B/C (5HT2A/B/C), 5HT1A, 5HT7, α2B, and dopamine-2/3 (D2/3) receptor subtypes with nanomolar affinity. Cabergoline was an agonist at human recombinant 5HT2, 5HT1A and D2/3 receptors but an antagonist at 5HT7 and α2 receptors. In primary human ciliary muscle (h-CM) and trabecular meshwork (h-TM) cells, cabergoline stimulated phosphoinositide (PI) hydrolysis (EC50 = 19 ± 7 nM in TM; 76 nM in h-CM) and intracellular Ca2+ ([Ca2+]i) mobilization (EC50 = 570 ± 83 nM in h-TM; EC50 = 900 ± 320 nM in h-CM). Cabergoline-induced [Ca2+]i mobilization in h-TM and h-CM cells was potently antagonized by a 5HT2A-selective antagonist (M-100907, Ki = 0.29–0.53 nM). Cabergoline also stimulated [Ca2+]i mobilization more potently via human cloned 5HT2A (EC50 = 63.4 ± 10.3 nM) than via 5HT2B and 5HT2C receptors. In h-CM cells, cabergoline (1 μM) stimulated production of pro-matrix metalloproteinases-1 and -3 and synergized with forskolin to enhance cAMP production. Cabergoline (1 μM) perfused through anterior segments of porcine eyes caused a significant (27%) increase in outflow facility. Topically administered cabergoline (300–500 μg) in Dutch-belted rabbit eyes yielded 4.5 μM and 1.97 μM levels in the aqueous humor 30 min and 90 min post-dose but failed to modulate intraocular pressure (IOP). However, cabergoline was an efficacious IOP-lowering agent in normotensive Brown Norway rats (25% IOP decrease with 6 μg at 4 h post-dose) and in conscious ocular hypertensive cynomolgus monkeys (peak reduction of 30.6 ± 3.6% with 50 μg at 3 h post-dose; 30.4 ± 4.5% with 500 μg at 7 h post-dose). In ketamine-sedated monkeys, IOP was significantly lowered at 2.5 h after the second topical ocular dose (300 μg) of cabergoline by 23% (p < 0.02) and 35% (p < 0.004) in normotensive and ocular hypertensive eyes, respectively. In normotensive eyes, cabergoline increased uveoscleral outflow (0.69 ± 0.7 μL/min–1.61 ± 0.97 μL/min, n = 13; p < 0.01). However, only seven of the eleven ocular hypertensive monkeys showed significantly increased uveoscleral outflow. These data indicate that cabergoline's most prominent agonist activity involves activation of 5HT2, 5HT1A, and D2/3 receptors. Since 5HT1A agonists, 5HT7 antagonists, and α2 antagonists do not lower IOP in conscious ocular hypertensive monkeys, the 5HT2 and dopaminergic agonist activities of cabergoline probably mediated the IOP reduction observed with this compound in this species." @default.
• W2007117923 created "2016-06-24" @default.
• W2007117923 creator A5005470167 @default.
• W2007117923 creator A5009530332 @default.
• W2007117923 creator A5011347947 @default.
• W2007117923 creator A5019901150 @default.
• W2007117923 creator A5024909155 @default.
• W2007117923 creator A5039302002 @default.
• W2007117923 creator A5044610870 @default.
• W2007117923 creator A5050414853 @default.
• W2007117923 creator A5061835154 @default.
• W2007117923 creator A5091104086 @default.
• W2007117923 date "2009-03-01" @default.
• W2007117923 modified "2023-10-16" @default.
• W2007117923 title "Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes" @default.
• W2007117923 cites W1571746100 @default.
• W2007117923 cites W1720110446 @default.
• W2007117923 cites W1963583141 @default.
• W2007117923 cites W1965637818 @default.
• W2007117923 cites W1966466693 @default.
• W2007117923 cites W1968587998 @default.
• W2007117923 cites W1968867545 @default.
• W2007117923 cites W1976155840 @default.
• W2007117923 cites W1976753543 @default.
• W2007117923 cites W1978208122 @default.
• W2007117923 cites W1979704173 @default.
• W2007117923 cites W1980753269 @default.
• W2007117923 cites W1985392788 @default.
• W2007117923 cites W1988852659 @default.
• W2007117923 cites W1989399186 @default.
• W2007117923 cites W1990667033 @default.
• W2007117923 cites W1992351557 @default.
• W2007117923 cites W1999167881 @default.
• W2007117923 cites W2000935282 @default.
• W2007117923 cites W2003535585 @default.
• W2007117923 cites W2006935174 @default.
• W2007117923 cites W2010608134 @default.
• W2007117923 cites W2016580510 @default.
• W2007117923 cites W2021325259 @default.
• W2007117923 cites W2022017995 @default.
• W2007117923 cites W2023905396 @default.
• W2007117923 cites W2025629751 @default.
• W2007117923 cites W2026020062 @default.
• W2007117923 cites W2029134234 @default.
• W2007117923 cites W2034742653 @default.
• W2007117923 cites W2038419068 @default.
• W2007117923 cites W2039518454 @default.
• W2007117923 cites W2040205334 @default.
• W2007117923 cites W2040423711 @default.
• W2007117923 cites W2040650357 @default.
• W2007117923 cites W2045856913 @default.
• W2007117923 cites W2046174900 @default.
• W2007117923 cites W2047189949 @default.
• W2007117923 cites W2047661963 @default.
• W2007117923 cites W2048686092 @default.
• W2007117923 cites W2050662511 @default.
• W2007117923 cites W2056607833 @default.
• W2007117923 cites W2068719363 @default.
• W2007117923 cites W2071297868 @default.
• W2007117923 cites W2072470029 @default.
• W2007117923 cites W2078348228 @default.
• W2007117923 cites W2079202995 @default.
• W2007117923 cites W2079307348 @default.
• W2007117923 cites W2081382151 @default.
• W2007117923 cites W2086107300 @default.
• W2007117923 cites W2091149498 @default.
• W2007117923 cites W2091655886 @default.
• W2007117923 cites W2095995222 @default.
• W2007117923 cites W2102418959 @default.
• W2007117923 cites W2119852373 @default.
• W2007117923 cites W2123915391 @default.
• W2007117923 cites W2126199231 @default.
• W2007117923 cites W2131933554 @default.
• W2007117923 cites W2133608824 @default.
• W2007117923 cites W2134598599 @default.
• W2007117923 cites W2145883438 @default.
• W2007117923 cites W2950966816 @default.
• W2007117923 cites W94835360 @default.
• W2007117923 doi "https://doi.org/10.1016/j.exer.2008.10.003" @default.
• W2007117923 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18992242" @default.
• W2007117923 hasPublicationYear "2009" @default.
• W2007117923 type Work @default.
• W2007117923 sameAs 2007117923 @default.
• W2007117923 citedByCount "32" @default.
• W2007117923 countsByYear W20071179232013 @default.
• W2007117923 countsByYear W20071179232014 @default.
• W2007117923 countsByYear W20071179232015 @default.
• W2007117923 countsByYear W20071179232016 @default.
• W2007117923 countsByYear W20071179232018 @default.
• W2007117923 countsByYear W20071179232019 @default.
• W2007117923 countsByYear W20071179232020 @default.
• W2007117923 countsByYear W20071179232021 @default.
• W2007117923 countsByYear W20071179232022 @default.
• W2007117923 countsByYear W20071179232023 @default.
• W2007117923 crossrefType "journal-article" @default.
• W2007117923 hasAuthorship W2007117923A5005470167 @default.
• W2007117923 hasAuthorship W2007117923A5009530332 @default.
• W2007117923 hasAuthorship W2007117923A5011347947 @default.

• next